Incyte | Lucro Bruto Sobre Vendas

Preço das Ações
101.23
Mudança Diária
1.14 1.14%
Mensal
0.05%
Anual
37.73%
Q1 Previsão
98.18




Lucro Bruto Sobre Vendas Alterar Data
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agenus USD 23.93M 2.79M 2025-03
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
BioCryst Pharmaceuticals USD -88.88M 202.74M 2024-12
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Eli Lilly USD 14.59B 1.48B 2025-09
Exelixis USD 572.18M 7M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Incyte USD 1.39B 118.68M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
MacroGenics USD 61.25M 88.71M 2025-09
Merck USD 13.42B 431M 2025-09
Moderna USD 226M 583M 2025-12
Nektar Therapeutics USD 13.75M 650K 2024-06
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.82B 695M 2025-09
Novartis USD 10.82B 694M 2025-09
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12


Incyte Lucro Bruto Sobre Vendas - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Feb 2026.